Rodríguez-Nóvoa Sonia, Morello Judit, González Mar, Vispo Eugenia, Barreiro Pablo, González-Pardo Gema, Jiménez-Nácher Inmaculada, Gonzalez-Lahoz Juan, Soriano Vincent
Pharmacokinetic and Pharmacogenetic Unit, Hospital Carlos III, Madrid, Spain.
AIDS. 2008 Nov 30;22(18):2535-7. doi: 10.1097/QAD.0b013e3283177f38.
Atazanavir use is associated with increases in serum bilirubin. Ribavirin, used to treat hepatitis-C infection, cause hemolysis and may worsen hyperbilirubinemia. We studied HIV/hepatitis-C virus-coinfected patients who initiated hepatitis-C therapy. Hyperbilirubinemia grade 3-4 increased from 9% to 45% after the start of hepatitis-C treatment in patients who used atazanavir concomitantly. Atazanavir use and hemoglobin (Hb) drops were predictors of increases in bilirubin. A substantial proportion of patients under atazanavir-therapy experienced significant hyperbilirubinemia and jaundice following initiation of hepatitis-C therapy.
使用阿扎那韦会导致血清胆红素升高。用于治疗丙型肝炎感染的利巴韦林会引起溶血，并可能使高胆红素血症恶化。我们研究了开始丙型肝炎治疗的HIV/丙型肝炎病毒合并感染患者。在同时使用阿扎那韦的患者中，丙型肝炎治疗开始后3 - 4级高胆红素血症从9%增加到45%。使用阿扎那韦和血红蛋白（Hb）下降是胆红素升高的预测因素。在开始丙型肝炎治疗后，相当一部分接受阿扎那韦治疗的患者出现了明显的高胆红素血症和黄疸。
